Carmel software firm in midst of expansion, 40 hires
Clinical Architecture is spending $4.2 million on its new headquarters space while seeking software developers, clinical experts, salespeople and product managers.
Health Care Businesses
Articles
West Lafayette biotech raises $40M to develop cancer-imaging drugs
The company said the funds would help it test its lead compound in late-stage clinical trials, allowing surgeons to detect cancerous cells with the help of fluorescent dyes.
IU Health pushes further into Fort Wayne, a market in upheaval
The Indianapolis-based health system said it will open a primary-care medical office in Fort Wayne early next year, and is examining “a long-term presence” in the market.
Study: Premiums for popular Obamacare plan up 34 percent
Premiums for the most popular Obamacare plans are going up an average of 34 percent nationwide, according to a new study. But the increases aren’t as high in Indiana.
Lilly shares slide on news of possible sale, spinoff of Elanco
Despite slipping sales and lost market share, the Elanco animal-health unit is strong and the time is right to explore selling or spinning it off, Eli Lilly and Co. officials said Tuesday.
Lilly plans $72M upgrade for Indianapolis insulin operation
The Indianapolis drugmaker said it will use the money to replace an existing line that fills vials for Humalog and Humulin and to prepare for new insulin products.
Device maker SonarMed ponders whether to go solo or find a partner
The Carmel-based company makes a device that uses sound waves to help position and monitor breathing tubes for newborns in hospitals.
Trump considers former Lilly exec for HHS post
Before joining Eli Lilly and Co., Alex Azar served as the general counsel and deputy secretary of Health and Human Services Administration under President George Bush.
Legal fight looms over California’s new drug pricing law
California has passed a law requiring pharmaceutical companies to explain their price increases, escalating the state-by-state battle between lawmakers trying to bring more transparency to the industry’s practices and drugmakers that oppose the efforts.
FDA approving drugs at accelerated pace
Thirty-four new drugs—treating everything from cancer to rare genetic diseases—have been approved so far this year. That’s on pace to nearly double last year’s approvals.
Struggling Endocyte spending millions for rights to prostate-cancer drug
After struggling for more than 20 years to develop cancer drugs without success, West Lafayette-based Endocyte Inc. is pausing it own R&D efforts to concentrate on a potential blockbuster drug from a German chemical company.
Lilly names new CFO, head of R&D
The appointments mark the latest changes in the Indianapolis-based drugmaker’s executive suite since David Ricks took over as CEO in January.
FDA approves Lilly drug for common advanced breast cancer
U.S. regulators have approved a new medicine for treating a common type of breast cancer after it has spread to other parts of the body.
EILENBERG: Is pharma the cause or solution to the opioid crisis?
Unfortunately, what started as a solution for pain turned into a crisis that is killing people.
Employers, workers brace for another round of health premium increases
The National Business Group on Health is projecting the total cost of providing medical and pharmacy benefits to increase 5 percent for the fifth consecutive year in 2018.
Lilly breast cancer drug results could challenge Pfizer pill
li Lilly and Co.’s experimental breast cancer drug abemaciclib, when combined with standard therapy, slowed the progression of tumors in patients with an advanced form of the disease.
Greenwood hospital closure to eliminate 86 jobs
The upcoming closure of Kindred Hospital Indianapolis South in Greenwood will take place in November, the hospital’s owner said Friday in a notice to the Indiana Department of Workforce Development.
Lilly eliminating 3,500 jobs as part of cost-cutting plan
Indianapolis-based pharmaceutical giant Eli Lilly and Co. said the 3,500 jobs represent 8.3 percent of its global workforce. Lilly hopes the cuts will save it $500 million a year.
Lilly competitor reaches $46.5M settlement with U.S. over safety info
Danish drugmaker Novo Nordisk says it has reached a settlement over allegations that it hadn’t properly communicated safety information when marketing a medicine to treat type 2 diabetes.
Lilly shares rise on surprising news from FDA on arthritis drug
The Indianapolis drugmaker said it will not be required to conduct another expensive, time-consuming clinical trial for the potential blockbuster.